IMVT - NASDAQ

Immunovant, Inc.

IMVT·NASDAQ

$31.15

+1.2%

HealthcareBiotechnology

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$6.40B

EPS-2.7700

P/E Ratio-11.25

Earnings Date06/04/2026

imvt

Depreciation and Amortization

Last Annual Value

409.00K

3-Year CAGR

28%

5-Year CAGR

-16%

10-Year CAGR

Adjust for Inflation

Immunovant, Inc. Competitors Analysis of Depreciation and Amortization

IMVT · NASDAQ

Company	Depreciation and Amortization	CAGR 3Y	CAGR 5Y	CAGR 10Y
Immunovant, Inc. NASDAQ:IMVT	409.00K	28.4%	-16.3%	N/A
Soleno Therapeutics, Inc. NASDAQ:SLNO	2.02M	1.0%	0.5%	31.4%
Kymera Therapeutics, Inc. NASDAQ:KYMR	8.31M	32.6%	28.2%	N/A
Viking Therapeutics, Inc. NASDAQ:VKTX	431.00K	13.9%	7.8%	-14.0%
Ultragenyx Pharmaceutical Inc. NASDAQ:RARE	0.00	N/A	N/A	N/A
Dyne Therapeutics, Inc. NASDAQ:DYN	2.05M	7.0%	13.5%	-44.7%
ACADIA Pharmaceuticals Inc. NASDAQ:ACAD	11.76M	28.4%	28.6%	20.5%
Crinetics Pharmaceuticals, Inc. NASDAQ:CRNX	3.89M	52.4%	33.4%	45.4%
NewAmsterdam Pharma Company N.V. NASDAQ:NAMS	220.00K	65.0%	113.2%	N/A
Akero Therapeutics, Inc. NASDAQ:AKRO	18.00K	-14.7%	-15.2%	N/A
Praxis Precision Medicines, Inc. NASDAQ:PRAX	-3.45M	N/A	N/A	N/A

Immunovant, Inc. Fair Value Envelope

IMVT · NASDAQ

Our analysis suggests that IMVT has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $31.15, this represents a potential HIDDEN relative to our calculated worth for Immunovant, Inc..

HIDDEN

Intrinsic Value

Current Price: $31.15

Related Guides

Blog Categories

Continue your IMVT research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.